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ABSTRACT
Introduction: Very little is known about the
prevalence of respiratory symptoms or their
associations with other health conditions in Russia.
Methods: Between 2008 and 2010, a sample of 983
men resident in Izhevsk, Russia, took part in a cross-
sectional survey. Presence of respiratory symptoms
was determined from self-report of chronic productive
cough and breathlessness assessed using the British
Medical Research Council (MRC) breathlessness scale.
Self-reported physical and mental health were
measured using the 12-Item Short-Form Health Survey
(SF-12). Hypertension was assessed from mean blood
pressure measured at the health check and/or self-
reported use of antihypertensive medication. Other
comorbidities were assessed from self-report. Logistic
regression models were fitted assessing the
association between respiratory symptoms and
comorbidities. Linear regression models were fitted to
investigate the association between respiratory
symptoms and self-reported health scores. All models
were adjusted for age, education and smoking status.
Results: The age-standardised prevalence of cough
and breathlessness was 20.9% (prevalence with
breathlessness MRC grade 3 or above 3.7%). The
majority of men with respiratory symptoms (87.3%)
were current smokers. Cough and breathlessness were
associated with substantially worse self-reported
physical and mental health (test for trend with severity
of breathlessness p<0.001). Those with chronic cough
and grade 3 or above breathlessness had higher odds
of having hypertension (OR 3.03; 95% CI 1.36 to
6.74), diabetes (OR 10.55; 95% CI 2.69 to 41.37),
angina pectoris (OR 7.54; 95% CI 3.61 to 15.73),
previous myocardial infarction (OR 7.61; 95% CI 2.10
to 27.4) and previous stroke (OR 6.61; 95% CI 1.75 to
23.34) compared with those without respiratory
symptoms.
Conclusions: The prevalence of respiratory symptoms
was high. Strong associations were found between
respiratory symptoms and cardiovascular
comorbidities. These are of particular importance given
the extremely high level of cardiovascular disease
mortality in Russia.
INTRODUCTION
Chronic respiratory diseases are a major cause
of morbidity and mortality worldwide.1 2
Tobacco smoking is an important risk
factor for lung disease.3 Prevalence of
smoking in Russia is very high among men,
estimated at 60.2% in the 2009 Global Adult
Tobacco Survey,4 and has shown no evidence
of a decline over time,5 6 thus suggesting that
the burden of chronic respiratory disease in
Russia is likely to be substantial. In addition,
occupational exposure to vapours, dusts and
fumes are likely to be important risk factors
for respiratory diseases among industrial
workers in Russia.7
Despite a high prevalence of smoking in
Russia, very little attention has been paid to
the burden of chronic respiratory problems
in the Russian population. We are aware of
only two studies investigating the prevalence
of respiratory symptoms in the general popu-
lation. Vietri et al8 found in the analyses of
5920 adults, aged 40 years or older in the
2011 Russia National Health and Wellness
Survey, that 54% of respondents reported
one or more symptoms of chronic respiratory
KEY MESSAGES
▸ The prevalence of respiratory symptoms in
Izhevsk was high and associated with substan-
tial cardiovascular comorbidity.
▸ The prevalence of smoking was extremely high
even among those with severe breathlessness,
suggesting the need for improved smoking ces-
sation treatment in those with respiratory
symptoms.
▸ This is one of the very few papers investigating
the burden of respiratory disease in the Russian
Federation and shows the need for further
research into this neglected area.
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disease (45% reported shortness of breath, 27%
reported coughing up mucous, and 18% reported
wheezing). Chuchalin et al9 found in a cross-sectional
survey of 7164 adults from 12 regions in Russia that
25.7% reported an attack of wheezing or whistling with
breathlessness and 8.6% reported symptoms of chronic
bronchitis. Both previous studies suggest that the preva-
lence of chronic respiratory disease in Russia is high.
Russia has one of the highest levels of cardiovascular
disease mortality in the world.10 There is evidence that
respiratory disease and cardiovascular disease are linked,
with associations found between cardiovascular morbid-
ity and mortality and chronic obstructive pulmonary
disease (COPD),11–16 asthma,17–19 and idiopathic pul-
monary ﬁbrosis.20 Cardiovascular disease is one of the
main causes of death in both patients with
COPD11 14 16 21 and asthma.22 23 The reasons for links
between respiratory and cardiovascular diseases are not
well understood. Some of these associations may be due
to smoking as a common cause; however, systemic
inﬂammation has also been suggested as a potential
mechanism.11 16 Despite the high prevalence of cardio-
vascular disease, to our knowledge, no previous studies
have investigated the association between respiratory and
cardiovascular morbidity in Russia.
The aim of this study was to investigate the prevalence
of respiratory symptoms (chronic productive cough and
breathlessness) and their associations with cardiovascular
risk factors and self-reported comorbidities among
working-age men in the city of Izhevsk, Russia.
METHODS
Study sample
The study sample was 938 working-age men (25–60 years
old) who were residents in the city of Izhevsk, an indus-
trial city in Russia located 1300 km south east of
Moscow, West of the Ural Mountains.
These men were participants in the Izhevsk Family
Study 2 (IFS-2). This was a follow-up study of 1941 men
living in Izhevsk originally recruited as population con-
trols in a case–control study of the association between
hazardous alcohol consumption and premature mortal-
ity in 2003–2006.24 The original controls were living
men frequency matched by age to cases (men aged 25–
54 years who had died in the past year) selected at
random from the population list of Izhevsk in 2002. In
IFS-2 (2008–2010), 1515 of these men were followed up,
interviewed by a trained interviewer and invited to
attend a health check. The health check conducted by a
doctor included questions on medical history, three
measurements of blood pressure and collection of a
blood sample. There were four different doctors who
conducted the health check. Participants were also given
a self-completed questionnaire which included the
12-Item Short-Form Health Survey (SF-12) questions.25
For the majority of men, the health check took place in
a polyclinic, but those who were unable to attend the
clinic were offered the option of having this done in
their own home.
Out of the 1515/2041 men successfully reinterviewed
as part of the IFS-2 study, 1052 attended the health
check. For the purposes of this study, the sample was
restricted to 983 men, with complete data collected on
self-reported respiratory symptoms. A ﬂow chart of par-
ticipation in the study is shown in ﬁgure 1.
IFS-2 was approved by the Ethics Committees of the
London School of Hygiene & Tropical Medicine and
Izhevsk Medical Academy. Informed written consent was
obtained from all participants to take part in the health
check.
Definition of respiratory symptoms
No spirometry data were collected at the health check;
therefore, it was not possible to investigate prevalence of
a speciﬁc disease such as COPD or asthma. However,
data were collected on self-reported respiratory symp-
toms (chronic productive cough and breathlessness).
Men who reported ‘Don’t know/difﬁcult to answer’ to
any of the questions were coded as missing data on self-
reported symptoms. The impact of this was assessed in
sensitivity analyses.
Chronic productive cough was deﬁned by one positive
answer to the following questions: ‘Do you usually cough
up any phlegm from your chest ﬁrst thing in morning in
winter?’, and/or ‘Do you usually cough up any phlegm
from your chest, during the day or at night in winter?’,
and/or ‘Do you bring up phlegm like this on most days
for as much as 3 months each year?’.
Breathlessness was deﬁned as a positive answer to one
or more of the questions: (1) ‘Are you troubled by short-
ness of breath when hurrying on level ground or
Figure 1 Flow chart of participants.
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walking up a slight hill?’, and/or (2) ‘Do you get short
of breath walking with people of your own age group on
level ground?’, and/or (3) ‘Do you have to stop for
breath when walking at your own pace on level
ground?’, and/or (4) ‘Have you had attacks of wheezing
or whistling in your chest at any time in the last 12
months?’, and/or (5) ‘Have you at any time in the past
12 months been woken at night by an attack of shortness
of breath?’.
Breathlessness questions 1, 2 and 3 are part of the UK
Medical Research Council (MRC) breathlessness scale, a
validated tool for measuring disability associated with
breathlessness,26 and were used to further divide men
with respiratory symptoms into those with breathlessness
grade 2 or less, and those with breathlessness grade 3 or
higher. Question 4 was used to identify prevalence of
wheeze and question 5, prevalence of nocturnal
dyspnoea.
Definition of exposures
Comorbidities
Comorbidities included were hypertension, diabetes,
angina, previous myocardial infarction (MI) and previ-
ous stroke. All data on comorbidities were collected at
the health check.
Three measurements of blood pressure were taken
during the health check. Men were categorised as
having hypertension if mean systolic blood pressure
using the second and third blood pressure measure-
ments was greater than 139 mm Hg or diastolic blood
pressure was greater than 89 mm Hg and/or participants
reported taking any antihypertensive medications either
daily or sometimes.
Angina was determined from self-reported angina
symptoms measured using the Rose angina
questionnaire.27
Classiﬁcation of diabetes mellitus, MI and stroke were
all assessed from self-report of these conditions.
Self-reported health
Self-reported physical and mental health were measured
using the SF-12, a standardised instrument for measur-
ing self-reported health, derived as a shorter alternative
to the SF-36.25 In accordance with standard practice, two
summary scales were derived from these questions: a
physical health component score and a mental health
component score. Both of these summary scores ranged
from 0 to 100.
Cardiovascular risk factors
Other exposures of interest were body mass index (BMI;
kg/m2), total cholesterol, high-density lipoprotein chol-
esterol (HDL-C), and triglycerides measured in mmol/
L, and B-type natriuretic peptide (BNP) measured in
pg/mL. BNP is a biomarker of heart failure which is
released with abnormal cardiac wall strain. Levels may
also be raised for other reasons, including age, myocar-
dial ischaemia, atrial ﬁbrillation and renal
dysfunction.28 29 BNP is an independent predictor of
cardiovascular morbidity and mortality,30 31 and has
been found to be strongly associated with hazardous
alcohol consumption in this population.32 The distribu-
tions of triglycerides and BNP were skewed; therefore,
these variables were transformed using the natural
logarithm.
Potential confounding variables
Age
Age was categorised into 5-year age groups and used as a
continuous variable in analyses.
Education
Three categories of education were used: incomplete
secondary, secondary, and higher or incomplete higher
education. Owing to data sparsity, education was used as
a continuous variable in analyses.
Smoking
Self-reported smoking status was categorised into ﬁve
groups: never smoked, ex-smoker, current smoker 1–5
cigarettes per day, current smoker 11–20 cigarettes per
day and current smoker >20 cigarettes per day.
Alcohol consumption
Alcohol consumption was considered as a potential con-
founder as it is strongly associated with smoking status
and is also an important predictor of general health
status and cardiovascular mortality in Russia.24 33 34
Two aspects of alcohol consumption in the past
12 months were considered: quantity of alcohol con-
sumed and hazardous drinking pattern. Quantity of
alcohol consumed was measured using total volume of
ethanol consumed in the past year calculated from ques-
tions on the frequency and usual quantity of beer, wine
and spirits consumed. Using an approach developed in
our previous work, men were also classiﬁed as non-
drinkers, non-hazardous drinkers and hazardous drin-
kers.24 35 Men were classiﬁed as hazardous drinkers if
they reported twice weekly or more frequency of hang-
over and/or excessive drunkenness and/or sleeping in
clothes at night because of drunkenness and/or failing
their family or personal obligations because of drinking
and/or drinking non-beverage alcohols (sources of
ethanol not intended for drinking such as eau de
cologne) and/or one or more episodes of zapoi (a
period of 2 or more days of drinking during which a par-
ticipant is withdrawn from normal social life).
Medication use
Men were asked to report all medications they were
taking at the time of the health check coded by a cardi-
ologist. Use of medication for a respiratory problem was
assessed by self-reported use of medications classiﬁed as
bronchodilators, glucocorticoids and mucolytics. Data
were not speciﬁcally collected on route of admission (ie,
oral or inhaled).
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Statistical analysis
The prevalence of chronic cough and breathlessness was
directly standardised by age using the 2013 European
Standard Population aged 25–59 years.
Logistic regression models were ﬁtted with each of the
cardiovascular comorbidities as the outcome (hyperten-
sion, diabetes, angina, MI and stroke) and respiratory
symptoms categorised by degree of breathlessness as the
exposure variable.
It was necessary to limit, where possible, the number
of confounders which could be included in the models
because of sparsity of data for four of the outcomes (dia-
betes, angina, MI and stroke). Models were adjusted for
age and education as a priori confounders and then
additionally for smoking status. Smoking was considered
as a potential confounder because it is strongly asso-
ciated with both respiratory and cardiovascular diseases.
However, smoking status could also be affected by both
respiratory and cardiovascular diseases, and as people
may stop smoking due to illness, adjustment could also
lead to spurious associations due to reverse causality.
Models were, therefore, considered with and without
adjustment for smoking status. Although alcohol con-
sumption was considered a priori as a potential confoun-
der, no strong associations were found between the two
different measures of alcohol use and respiratory symp-
toms in univariate analysis; therefore, alcohol consump-
tion was not included as a confounder in the ﬁnal
model.
The associations between self-reported physical and
mental health components of the SF-12 and serum
lipids (total cholesterol, HDL-C and triglycerides), BNP
and BMI were assessed using linear regression models
with self-reported respiratory symptoms as exposure vari-
ables. Models were adjusted for age, education and
smoking status.
Sensitivity analysis
There were 63 men who answered “don’t know” to at
least one question on their respiratory symptoms. In the
main analyses, these men were excluded as missing.
However, a sensitivity analysis was carried out ﬁrst recate-
gorising ‘don’t know’ answers to ‘no’ for that particular
question, and then recategorising ‘don’t know’ answers
to ‘yes’ for that particular question. Analyses were rerun
under these two alternative scenarios.
RESULTS
Overall data were available on symptoms of chronic
cough and breathlessness for 983 men. There were no
differences in these men with respect to age, education,
smoking status or alcohol use from data available on
respiratory symptoms compared with all the 1515 men
who were interviewed in the IFS-2 study.
In the population, overall prevalence of chronic
cough was 44.0% (n=432), breathlessness (grade 2 or
above) was 33.9% (n=333), breathlessness (grade 3 or
above) was 8.9% (n=87), wheeze was 4.3% (n=42), and
nocturnal dyspnoea was 3.2% (n=31).There were 204
men (20.8%) who reported symptoms of both cough
and breathlessness (age-standardised prevalence 20.9%
(95% CI 18.4% to 23.5%)). Among men with chronic
cough, 49 (24.0%) reported grade 3 or above breathless-
ness. The prevalence of wheeze among those with
chronic cough and breathlessness was 16.7% (34 men)
and nocturnal dyspnoea 11.4% (23 men). The preva-
lence of respiratory symptoms by smoking status is
shown in table 1.
The level of use of medications for respiratory pro-
blems was very low. Ten men reported using bronchodi-
lators (seven with symptoms of chronic cough and
breathlessness). Four men reported using glucocorti-
coids (two with symptoms of chronic cough and breath-
lessness) and seven men reported use of mucolytics
(three with symptoms of chronic cough and
breathlessness).
The majority of men with chronic cough and
breathlessness were current smokers (87.3%).There
was no evidence of a systematic difference in smoking
behaviour by grade of breathlessness (p=0.54) despite
a higher percentage of ex-smokers in those with
breathlessness grade 3 or above compared with those
Table 1 Prevalence of self-reported respiratory symptoms by smoking status
Respiratory symptom
Non-smoker Ex-smoker
Current
smoker All men
N (%) N (%) N (%) N (%)
Chronic productive cough 24 (12.6) 40 (21.7) 368 (60.6) 432 (44.0)
MRC breathlessness grade 2 34 (17.8) 39 (21.2) 173 (28.5) 246 (25.1)
MRC breathlessness grade 3 and above 11 (5.8) 18 (9.8) 58 (9.6) 87 (8.9)
Wheeze 5 (2.6) 4 (2.2) 33 (5.4) 42 (4.3)
Nocturnal dyspnoea 6 (3.1) 6 (3.3) 19 (3.1) 31 (3.2)
Chronic cough and breathlessness* 9 (4.7) 17 (9.2) 178 (29.3) 204 (20.8)
Total 191 (100) 184 (100) 607 (100) 982† (100)
*Breathlessness defined as MRC breathless grade 2 or above and/or wheeze and/or nocturnal dyspnoea.
†Smoking status missing for one man.
MRC, Medical Research Council.
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with grade 2 breathlessness (6.5% vs 14.3%). The dis-
tribution of men with and without symptoms of
chronic cough and breathlessness by sociodemo-
graphic factors, smoking, cardiovascular risk factors,
self-reported health and comorbidities is shown in
table 2. There was strong evidence of an association
between self-reported symptoms of chronic cough
and breathlessness and education. The proportion of
men with higher education decreased as severity of
breathlessness increased. Different patterns emerged
for the two measures of alcohol use: total volume
consumed was highest among men with chronic
cough and MRC breathlessness of grade 2 or less, but
lowest among men with chronic cough and MRC
breathlessness grade 3 or less. Conversely, the propor-
tion of hazardous drinkers in the sample increased
with severity of breathlessness. However, there was
only weak evidence for an association with either
measure of alcohol use and self-reported symptoms
of chronic cough and breathlessness.
The cross-sectional associations between self-reported
chronic cough and breathlessness and comorbidities are
shown in table 3. The odds of hypertension, diabetes,
angina, MI and stroke were all raised in men with self-
reported cough with breathlessness of grade 3 or above
compared with men with no respiratory symptoms.
There was strong evidence that the odds of diabetes,
angina and MI, and good evidence that the odds of
hypertension and stroke increased with severity of
breathlessness. These associations remained on adjusting
for smoking.
The cross-sectional associations between self-
reported chronic cough and breathlessness symptoms,
self-reported health, serum lipids, BNP, and BMI are
shown in table 4. There was strong evidence for a
substantial decrease in physical self-reported health
score with severity of breathlessness symptoms as men
with cough and grade 3 breathlessness had a mean
physical health score 11.58 points (95% CI 9.34 to
13.83) lower than men who did not report any
respiratory symptoms. There was also a corresponding
but smaller inverse trend in self-reported mental
health (men with grade 3 breathlessness reported a
mean mental health score 5.90 points lower than
men with no respiratory symptoms (95% CI 8.51 to
3.29)). There was some evidence for a negative associ-
ation with total cholesterol (test for trend p=0.06)
and HDL-C (test for trend p=0.01) and respiratory
symptoms with evidence of a decrease with increasing
severity of breathlessness. Mean BMI was higher in
men with chronic cough and breathlessness; there
was strong evidence for a positive trend with severity
of breathlessness (test for trend p<0.001). There was
also good evidence of a positive trend in log BNP
with severity of breathlessness (test for trend
p=0.006). There was no evidence for an association
between respiratory symptoms and triglycerides (test
for trend p=0.56).
Sensitivity analyses
When men who answered ‘don’t know’ to any particular
question were included, the sample size was 1046.
Assuming that all men who answered ‘don’t know’ did
not have the symptom, the prevalence of cough was
45.4%, any breathlessness was 34.5%, breathlessness
grade 3 or above was 9.3%, and for both cough and
breathlessness was 21.9%. Under the alternative scenario
that all men who answered ‘don’t know’ did have that
symptom, the prevalence of cough was 45.8%, any
breathlessness was 37.2%, breathlessness grade 3 or
above was 11.6%, and for both cough and breathlessness
was 23.5%. The substantive associations between self-
reported cough and breathlessness and the other health
outcomes were not altered under either scenario with
the exception that in both the sensitivity analyses, no
associations were seen between self-reported respiratory
symptoms and total cholesterol (data not shown).
DISCUSSION
In this sample of working-age men living in the indus-
trial city of Izhevsk, the age-standardised prevalence of
self-reported symptoms of chronic cough and breathless-
ness was 20.9% (age-standardised prevalence of chronic
cough with grade 3 or above breathlessness was 3.7%).
The prevalence of chronic cough was 44.0% and breath-
lessness grade 2 or above was 33.9%. This is high com-
pared with a prevalence of self-reported cough and/or
breathlessness from the BREATHE study of 12.2%
among 31 418 men living in 11 countries in the Middle
East and North Africa.36 The prevalence of cough and
breathlessness among men in Izhvesk was higher than
for any of the countries included in the BREATHE study
(range 6.1% in the United Arab Emirates to15.9% in
Pakistan). Chronic cough and breathlessness are both
symptoms of COPD and the high prevalence of these
symptoms suggests prevalence of COPD is likely to be
high in this population. This is consistent with the one
previous study which has investigated prevalence of
COPD in Russia using spirometry; the study estimated
overall prevalence in both men and women of 15.3%9
compared with an international prevalence of 10.1% in
the BOLD study (11.8% in men).37 Further studies in
Russia using spirometry are needed to provide more reli-
able estimates of the burden of COPD.
In this study, self-reported symptoms of cough and
breathlessness were associated with poorer self-reported
physical and mental health as assessed by the SF-12.
There was a particularly strong association with physical
health; men with chronic cough and grade 3 breathless-
ness or above had a physical health score 11.6 points
(95% CI 9.3 to 13.8) lower than men without any
respiratory symptoms, indicating the severe impact of
impaired respiratory function on quality of life for these
men. Men with chronic cough and grade 3 or above
breathlessness also had much higher odds of several
comorbidities (hypertension, diabetes, angina pectoris,
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Table 2 Distribution of sample by chronic cough and MRC breathlessness grade, sociodemographic variables, smoking,
cardiovascular risk factors and health status
No respiratory symptoms Chronic cough and breathlessness
≤Grade 2 breathlessness ≥Grade 3 breathlessness
N, mean or
median
(%,SD or
IQR)
N, mean or
median
(%, SD or
IQR)
N, mean or
median
(%, SD or
IQR)
Age (years)
25–29 10 (1.3) 3 (1.9) 0 (0.0)
30–34 58 (7.5) 12 (7.7) 2 (4.1)
35–39 63 (8.1) 20 (12.9) 4 (8.2)
40–44 96 (12.3) 14 (9.0) 3 (6.1)
45–49 160 (20.5) 29 (18.7) 3 (6.1)
50–54 187 (24.0) 34 (21.9) 12 (24.5)
55–60 205 (26.3) 43 (27.7) 25 (51.0)
χ2 (df) 23.13 (12) p=0.03
Education
Incomplete secondary 31 (4.0) 9 (5.8) 3 (6.1)
Secondary 556 (71.4) 123 (79.4) 43 (87.8)
Higher or incomplete higher 192 (24.7) 23 (14.8) 3 (6.1)
χ2 (df) 15.5 (4) p=0.004
Smoking status (missing=1)
Never smoked 182 (23.4) 7 (4.5) 2 (4.1)
Ex-smoker 167 (21.5) 10 (6.5) 7 (14.3)
Current smoker (1–10/day) 81 (10.4) 25 (16.1) 7 (14.3)
Current smoker (11–20/day) 274 (35.2) 82 (52.9) 25 (51.0)
Current smoker (>20/day) 74 (9.5) 31 (20.0) 8 (16.3)
χ2 (df) 75.9 (8) p<0.001
Total volume of ethanol (litres per year) (missing=13)
Median (IQR) 4.0 (1.2–10.1) 5.9 (1.7–12.5) 3.1 (1.2–17.3)
Kruskal-Wallis p=0.13
Hazardous drinker (missing=12)
Non-drinker 104 (13.5) 18 (11.7) 6 (12.2)
Drinker (non-hazardous) 602 (78.4) 117 (76.0) 34 (69.4)
Drinker (hazardous) 62 (8.1) 19 (12.3) 9 (18.4)
χ2 (df) 8.03 (4) p=0.09
Body mass index (missing=4)
Mean (SD) 26.2 (4.2) 26.4 (4.7) 27.8 (5.2)
Test for trend p=0.04
Total cholesterol mmol/L (missing=66)
Mean (SD) 5.44 (1.02) 5.27 (0.96) 5.22 (1.01)
Test for trend p=0.03
HDL-C mmol/L (missing=66)
Mean (SD) 1.44 (0.44) 1.40 (0.48) 1.36 (0.40)
Test for trend p=0.14
Log triglycerides (missing=82)
Mean (SD) 0.29 (0.51) 0.26 (0.50) 0.30 (0.52)
Test for trend p=0.73
Log BNP pg/mL (missing=74)
Mean (SD) 2.42 (0.87) 2.59 (1.03) 2.99 (0.96)
Test for trend p<0.001
SF-12 (missing=15)
Mean Physical health score
(SD)
48.8 (7.7) 45.2 (7.7) 36.1 (9.3)
Test for trend p<0.001
Mean Mental health score
(SD)
49.2 (8.6) 47.9 (8.8) 43.6 (10.3)
Test for trend p<0.001
Hypertension (missing=2)
Yes 477 (61.4) 97 (62.6) 41 (83.7)
χ2 (df) 9.79(2) p=0.007
Continued
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MI and stroke) compared with men without respiratory
symptoms, even after adjusting for smoking status. These
strong associations are consistent with the ﬁndings from
other countries that respiratory diseases, in particular
COPD, are associated with substantial cardiovascular
morbidity.11–13 15 17–20 The association between respira-
tory symptoms and cardiovascular morbidity has not
been investigated previously in Russia. The strong asso-
ciations with other health conditions found in this study
have implications for management of patients with
respiratory symptoms; these patients could beneﬁt from
identiﬁcation and treatment of comorbidities. Along
with increased odds of cardiovascular comorbidities,
men in Izhvesk with respiratory symptoms also had on
average a worse cardiovascular risk proﬁle with higher
BMI and lower HDL-C levels; however, total cholesterol
was also lower and no association was found with
triglycerides. There was also strong evidence of higher
levels of BNP with respiratory symptoms. Some of this
association may be due to misclassiﬁcation of heart
failure as a respiratory problem in this study since
breathlessness is a symptom of both; however, this
ﬁnding is consistent with previous studies which have
found both higher levels of BNP among patients with
COPD compared with healthy controls38 and that heart
failure is a common comorbidity among those with
COPD.39 There were only weak associations found in
this study between alcohol consumption and respiratory
symptoms despite strong associations between hazardous
alcohol consumption and blood pressure, cardiovascular
disease and BNP.32 33 40–43 Given the very high levels of
cardiovascular mortality in Russia, the identiﬁcation of
patients with respiratory problems as a potentially high-
risk group who may beneﬁt from primary and secondary
Table 2 Continued
No respiratory symptoms Chronic cough and breathlessness
≤Grade 2 breathlessness ≥Grade 3 breathlessness
N, mean or
median
(%,SD or
IQR)
N, mean or
median
(%, SD or
IQR)
N, mean or
median
(%, SD or
IQR)
Diabetes (Missing=7)
Yes 9 (1.2) 3 (2.0) 4 (8.3)
χ2 (df) 14.54 (2) p=0.001
Angina (missing=9)
Yes 43 (5.6) 24 (15.6) 14 (29.2)
χ2 (df) 45.7 (2) p<0.001
Myocardial infarction (missing=2)
Yes 11 (1.4) 2 (1.3) 5 (10.2)
χ2 (df) 20.1 (2) p<0.001
Stroke (missing=3)
Yes 8 (1.0) 1 (0.70) 4 (8.2)
χ2 (df) 18.6 (2) p<0.001
Total 779 (100) 155 (100) 49 (100)
BNP, B-type natriuretic peptide; HDL-C, high-density lipoprotein cholesterol; SF-12, 12-Item Short-Form Health Survey.
Table 3 Association between self-reported chronic cough and breathlessness symptoms and other comorbidities
Self-reported comorbidity
No respiratory
symptoms
Chronic cough and breathlessness
Test for
trend
≤Grade 2
breathlessness
≥Grade 3
breathlessnessOdds ratio (95% CI)
Hypertension (n=980) Model 1 1 (ref) 1.12 (0.77 to 1.62) 2.84 (1.29 to 6.26) p=0.04
Model 2 1 (ref) 1.19 (0.81 to 1.74) 3.03 (1.36 to 6.74) p=0.02
Diabetes (n=975) Model 1 1 (ref) 1.86 (0.49 to 7.03) 7.27 (2.05 to 25.85) p=0.008
Model 2 1 (ref) 2.91 (0.68 to 12.37) 10.55 (2.69 to 41.37) p=0.002
Angina (n=973) Model 1 1 (ref) 3.29 (1.91 to 5.65) 6.74 (3.31 to 13.75) p<0.001
Model 2 1 (ref) 3.73 (2.09 to 6.66) 7.54 (3.61 to 15.73) p<0.001
Myocardial infarction
(n=980)*
Model 1 1 (ref) 0.91 (0.20 to 4.20) 5.18 (1.65 to 16.22) p=0.04
Model 2 1 (ref) 1.40 (0.27 to 7.17) 7.61 (2.10 to 27.49) p=0.008
Stroke (n=979)* Model 1 1 (ref) 0.71 (0.09 to 5.77) 7.76 (2.09 to 28.88) p=0.03
Model 2 1 (ref) 0.60 (0.07 to 5.01) 6.61 (1.73 to 25.34) p=0.06
Model 1: adjusted for age and education.
Model 2: model 1 + smoking status.
*For myocardial infarction and stroke, the smoking variable was recoded so that the category >20 cigarettes/day merged with 11–20 cigarettes
per day; otherwise 113 observations dropped due to perfect prediction.
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prevention could be particularly important. Conversely,
respiratory function should also be investigated among
those with cardiovascular disease.
In this study the majority of men (87.3%) who
reported respiratory symptoms continued to smoke. This
was the case even for men experiencing more severe
breathlessness (81.6% current smokers). Smoking cessa-
tion is a key part of treatment for many respiratory con-
ditions. This is the single most effective treatment for
COPD with an important role in slowing the disease pro-
gression.14 44 An estimated 62% of patients with COPD
in the UK are current smokers estimated from a random
sample of patients with COPD in the UK population
registered with general practitioner practices in the
Clinical Practice Research Datalink.45 Although not dir-
ectly comparable, the ﬁndings from Izhvesk are consist-
ent with ﬁndings from this study and studies in clinical
populations that a large proportion of those with COPD
continue to smoke despite their disease.46 Smoking ces-
sation treatment has been found to be effective for redu-
cing smoking in patients with COPD46–49 and should be
offered routinely to those reporting respiratory
symptoms.
There were several limitations to this study. First spir-
ometry was not carried out at the health check.
Self-reported symptoms of cough and breathlessness
were used here to make some inference about chronic
respiratory disease burden overall and its associations
with cardiovascular comorbidities in this population. We
would like to use these ﬁndings to make some infer-
ences particularly about COPD, but this should be done
with caution given that the case deﬁnition used here is
less speciﬁc than COPD as determined by spirometry,
and that some men with cough and breathlessness in
this study may have had other lung conditions such as
asthma or tuberculosis. In addition, all comorbidities
were also self-reported which is an additional source of
measurement error. A further limitation in considering
the prevalence estimates is that the study population was
a small subset of men aged 25–59 years living in the city
of Izhevsk; therefore, the results on prevalence are not
generalisable to women, older men or to men living
elsewhere in Russia and estimates of prevalence are
likely to be imprecise. However, the ﬁnding that preva-
lence of chronic cough and breathlessness is high is con-
sistent with ﬁndings from other studies in Russia.8 9
There may also have been some selection bias in the
study since only 65% of men interviewed at IFS-2 went
on to attend the health check. However, no differences
were found between men included in this study and all
men taking part in IFS-2.
A further limitation was that no data were collected
about clinical diagnoses and data collected on treatment
were limited. Men were asked about what medications
they were taking. However, this question did not refer
speciﬁcally to inhalers and it is possible many men did
not report these. Only 10 men reported the use of
bronchodilators in the sample overall, but it is not pos-
sible to disentangle whether this is due to very low levels
of treatment with bronchodilators or under-reporting of
use of these medications. There seems to be a very low
level of use of bronchodilators given that some men are
likely to have been prescribed bronchodilators for
asthma, though it is worth noting that bronchodilators
could be expensive for a substantial proportion of the
population as Russian patients need to pay the full cost
of their medications. It was, however, possible to look at
the prevalence of smoking cessation, an important
Table 4 Association between self-reported chronic cough and breathlessness symptoms and self-reported health, lipids,
BNP and body mass index
No respiratory
symptoms
Chronic cough and breathlessness
Test for
trend
≤Grade 2
breathlessness
≥Grade 3
breathlessnessCoefficient (95% CI)
SF-12 PCS (n=967) Model 1 1 (ref) −3.49 (−4.80 to −2.18) −11.56 (−13.78 to −9.33) p<0.001
Model 2 1 (ref) −3.60 (−4.95 to −2.25) −11.58 (−13.83 to −9.34) p<0.001
SF-12 MCS (n=967) Model 1 1 (ref) −1.36 (−2.88 to 0.16) −5.97 (−8.55 to −3.39) p<0.001
Model 2 1 (ref) −1.33 (−2.90 to 0.24) −5.90 (−8.51 to −3.29) p<0.001
Total cholesterol
(n=916)
Model 1 1 (ref) −0.16 (−0.33 to 0.02) −0.25 (−0.55 to 0.05) p=0.02
Model 2 1 (ref) −0.13 (−0.31 to 0.06) −0.23 (−0.53 to 0.08) p=0.06
HDL-C (n=916) Model 1 1 (ref) −0.05 (−0.13 to 0.03) −0.10 (−0.23 to 0.03) p=0.07
Model 2 1 (ref) −0.08 (−0.16 to 0.002) −0.13 (−0.26 to 0.01) p=0.01
Log triglycerides
(n=900)
Model 1 1 (ref) −0.02 (−0.11 to 0.07) 0.02 (−0.14 to 0.17) p=0.88
Model 2 1 (ref) 0.01 (−0.08 to 0.11) 0.04 (−0.11 to 0.20) p=0.56
Log BNP (n=908) Model 1 1 (ref) 0.16 (0.003 to 0.31) 4.14 (0.16 to 0.67) p=0.001
Model 2 1 (ref) 0.11 (−0.05 to 0.26) 0.37 (0.12 to 0.63) p=0.006
Body mass index
(n=978)
Model 1 1 (ref) 0.37 (−0.38 to 1.12) 1.86 (0.60 to 3.12) p=0.01
Model 2 1 (ref) 0.95 (0.19 to 1.70) 2.29 (1.05 to 3.53) p<0.001
Model 1: adjusted for age and education.
Model 2: model 1 + smoking status.
BNP, B-type natriuretic peptide; HDL-C, high-density lipoprotein cholesterol; MCS, mental health component score; PCS, physical health
component score; SF-12, 12-Item Short-Form Health Survey.
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aspect of treatment for respiratory disease. The high
proportion of current smokers with respiratory symp-
toms supports ﬁndings from medication data that treat-
ment levels in this population are low. Finally there was
a low prevalence of several of the comorbidities
included, in particular stroke, diabetes and MI; there-
fore, results are based on small numbers and a limited
number of potential confounders were included.
Despite these limitations, the ﬁnding of a high level of
self-reported chronic cough and breathlessness in this
study is important given the very limited data available
on the burden of chronic respiratory conditions in the
Russian Federation.
In conclusion, in this sample of working-age men
living in Izhevsk, the prevalence of chronic cough and
breathlessness was high and associated with worse self-
reported physical and mental health and higher levels
of cardiovascular comorbidities. Despite the importance
of smoking cessation in treatment for respiratory dis-
eases, the majority of men with chronic cough and
breathlessness in this population continued to smoke,
thus showing that this is not being tackled sufﬁciently.
Chronic respiratory disease is an important public
health issue for Russia, but the low levels of research
published suggest this is a neglected area. More research
is needed, speciﬁcally around the levels of diagnosis and
treatment in Russia. The association between respiratory
symptoms and cardiovascular comorbidity is of particu-
lar importance given the extremely high levels of cardio-
vascular mortality in Russia.
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